The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Open accessAbstract
BACKGROUND: Plasma triglyceride levels are heritable and are correlated with the risk of coronary heart disease. Sequencing of the protein-coding regions of the human genome (the exome) has the potential to identify rare mutations that have a large effect on phenotype. METHODS: We sequenced the protein-coding regions of 18,666 genes in each of 3734 participants of European or African ancestry in the Exome Sequencing Project. We conducted tests to determine whether rare mutations in coding sequence, individually or in aggregate within a gene, were associated with plasma triglyceride levels. For mutations associated with triglyceride levels, we subsequently evaluated their association with the risk of coronary heart disease in 110,970 persons. RESULTS: An aggregate of rare mutations in the gene encoding apolipoprotein C3 (APOC3) was associated with lower plasma triglyceride levels. Among the four mutations that drove this result, three were loss-of-function mutations: a nonsense mutation (R19X) and two splice-site mutations (IVS2+1G→A and IVS3+1G→T). The fourth was a missense mutation (A43T). Approximately 1 in 150 persons in the study was a heterozygous carrier of at least one of these four mutations. Triglyceride levels in the carriers were 39% lower than levels in noncarriers (P<1×10(-20)), and circulating levels of APOC3 in carriers were 46% lower than levels in noncarriers (P=8×10(-10)). The risk of coronary heart disease among 498 carriers of any rare APOC3 mutation was 40% lower than the risk among 110,472 noncarriers (odds ratio, 0.60; 95% confidence interval, 0.47 to 0.75; P=4×10(-6)). CONCLUSIONS: Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease. (Funded by the National Heart, Lung, and Blood Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [60]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrary, loss-of-function mutations of the ApoC-III are associated with a lower risk of CVD [170–172].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, loss-of-function mutations in APOC3, which encodes apolipoprotein C-III, result in significantly lower plasma TG levels and confer a 40–50% lower risk of ischemic cardiovascular events [25].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss-of-function variants in APOC3 confer protection against coronary artery disease, independent of LDL cholesterol levels [60, 112]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [60]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with loss-of-function mutations in APOC-III exhibit significantly reduced levels of triglycerides and remnant cholesterol, along with a nearly 40% reduction in ASCVD risk [32, 33].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Individuals with genetic loss-of-function mutations in the APOC3 gene exhibit markedly lower TG levels and reduced incidence of CAD, highlighting apoC-III as a compelling therapeutic target for HTG and associated complications [25, 29, 43].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, with genetic studies supporting the role of several novel therapeutic targets (eg, apo C-III and ANGPTL3) in atherosclerosis, ongoing clinical trials using RNA interference therapy (antisense oligonucleotides and small interfering RNAs) have the potential to further inform our understanding of the triglyceride-based atherosclerotic pathways (120,121).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [120]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin vs placebo on background statin therapy in individuals with established ASCVD did not demonstrate a reduction in vascular events”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [64]
In the citing paper
“ApoCIII has been identified as a potentially important new risk factor. 104-106”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD. 106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
Multi-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
Robust relationship inference in genome-wide association studies
Manichaikul, A., Mychaleckyj, J. C., Rich, S. S., Daly, K., Sale, M., & Chen, W.-M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq559 · Cited by 3,541
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Flagged first, then by citations
1 of the 66 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Taylor HA, 2005, Ethn Dis, 15, S4
Cited by
Sorted by citations
Items 801–900 of 1,001
Pan, Z., Zaman, M. A., Kalsoom, S., & Zhang, Y. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2423724 · Cited by 4
Fu, L., Liu, Q., Cheng, H., Zhao, X., Xiong, J., & Mi, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038857 · Cited by 4
Pan, J. B., Wang, X., Zhang, Y., Wang, T., Lv, S., Zhang, X., Zhou, Y., Peng, T., & Song, Y. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70542 · Cited by 4
MEASURES OF EXPOSURE IMPACT GENETIC ASSOCIATION STUDIES: AN EXAMPLE IN VITAMIN K LEVELS AND VKORC1
Crawford, D. C., Brown-Gentry, K. D., & Rieder, M. J. (2014) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814644730_0017 · Cited by 4
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.958147 · Cited by 4
Crandell, J. R. (2016) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s38123 · Cited by 4
Wu, N. Q., Li, S., Zhang, Y., Zhu, C. G., Guo, Y. L., Gao, Y., Qing, P., Sun, J., Liu, G., Dong, Q., et al. (2017) · PubMed · doi:10.3967/bes2017.001 · Cited by 4
Bozzetto, L., Berntzen, B. J., Kaprio, J. A., Rissanen, A., Taskinen, M., & Pietiläinen, K. H. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.10.005 · Cited by 4
Peng, Y., Chen, G., & Zheng, H. (2020) · PubMed Central · doi:10.12122/j.issn.1673-4254.2020.08.11 · Cited by 4
Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis
Scheja, L., & Heeren, J. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_363 · Cited by 4
Uncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.04.002 · Cited by 4
Personalized Management of Cardiovascular Disorders
Jain, K. K. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2553-7_14 · Cited by 4
Pinder, M. I. M., & Töpel, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-92499-7_4 · Cited by 4
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Liu, L., Chen, J., Li, J., Yang, Y., Zeng, X., & Tian, X. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s377402 · Cited by 4
Majithia, A. R., Altshuler, D., & Hirschhorn, J. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00004-6 · Cited by 4
Plasma Proteome Profiles of Stable CAD Patients Stratified According to Total Apo C‐III Levels
Manfredi, M., Chiariello, C., Conte, E., Castagna, A., Robotti, E., Gosetti, F., Patrone, M., Martinelli, N., Bassi, A., Cecconi, D., et al. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201800023 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Orringer, C. E. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.04.009 · Cited by 5
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.12.001 · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 4
New and Emerging Therapies for Dyslipidemia
Zambon, A., Averna, M. R., D’Erasmo, L., Arca, M., & Catapano, A. L. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.004 · Cited by 4
Hallengren, E., Almgren, P., Engström, G., Persson, M., & Melander, O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128348 · Cited by 4
Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a)
Hanßen, R., & Gouni‐Berthold, I. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0115-0 · Cited by 4
Narzo, A. D., Frades, I., Crane, H. M., Crane, P. K., Hulot, J., Kasarskis, A., Hart, A. B., Argmann, C., Dubinsky, M. C., Peter, I., et al. (2021) · Human Genetics · doi:10.1007/s00439-020-02250-3 · Cited by 4
Cohort-wide deep whole genome sequencing and the allelic architecture of complex traitsPreprint
Gilly, A., Süveges, D., Kuchenbaecker, K. B., Pollard, M., Southam, L., Hatzikotoulas, K., Farmaki, A., Bjørnland, T., Waples, R. K., Appel, E. V. R., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/283481 · Cited by 4
Davidson, J., & Rotondo, D. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000510 · Cited by 4
Molecular Genetics of Coronary Artery Disease
Ozaki, K. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0027329 · Cited by 5
Bioinformatics Principles for Deciphering Cardiovascular Diseases
Shu, L., Arneson, D. V., & Yang, X. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99576-0 · Cited by 4
Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease
Natarajan, P. (2024) · New England Journal of Medicine · doi:10.1056/nejme2405647 · Cited by 4
Tang, X. L., Hooper, A. J., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2414126 · Cited by 4
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
Diagnosis, Evaluation, and Management of Severe Hypertriglyceridemia
Krishnamurthy, A., Homan, E. A., & Kim, S. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00758-9 · Cited by 4
Farstad-O’Halloran, K., Sooda, A., Iqbal, T., Wilton, S. D., & Aung-Htut, M. T. (2025) · Genes · doi:10.3390/genes16040412 · Cited by 3
Apolipoprotein C3 Promotes Angiogenesis in an Inflammatory Mouse Model of Peripheral Artery Disease
Thomas, J., Bamhare, P. M., Mulangala, J., Bursill, C. A., Nicholls, S. J., Bartolo, B. A. D., & Bubb, K. J. (2025) · The FASEB Journal · doi:10.1096/fj.202502155r · Cited by 3
Lipid lowering therapies in chronic kidney disease: A call to action
Ruiz, J. M., Arroyo, D., de Cos, M., Fernández, M. R., Sánchez-Álvarez, E., Bores, P. G., Hernández, J. L., & Corral, P. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120563 · Cited by 4
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
Nguyen, T. N., Kim, H.-J., Shim, H. M., Kang, J., Ha, E. Y., Cho, H., & Park, J. (2026) · Biomolecules · doi:10.3390/biom16040607 · Cited by 3
Genetische Diagnostik polygener Erkrankungen
Trenkwalder, T., Kessler, T., & Schunkert, H. (2017) · Herz · doi:10.1007/s00059-017-4576-z · Cited by 4
Li, W., Wang, Y., Huang, R., Feng, L., Xu, G.-X., Wang, W., & Xue, S. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03759-5 · Cited by 3
Bencun, M., Spreyer, L., Boileau, E., Eschenbach, J., Frey, N., Dieterich, C., & Völkers, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-87107-3 · Cited by 4
Joint health status in people with moderate hemophilia A: a cross-sectional multicenter study
Calcaterra, I. L., Picasso, F., Valeri, F., Baldacci, E., Napolitano, M., Guerrino, C., Zanon, E., Santoro, C., Siragusa, S., Martinoli, C., et al. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102737 · Cited by 3
Zambon, A., Gentile, L., Galimberti, F., Manzato, E., Giaccari, A., Sesti, G., Belfiore, A., Norata, G. D., Temporelli, P. L., Frulloni, L., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104214 · Cited by 3
Moll, T. O. C., Kiefer, J. G., Klemek, M. L., Wilson, M. H., & Farber, S. A. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322969 · Cited by 3
NHLBI Strategic Visioning: setting an agenda together for the NHLBI of 2025
Hoots, W. K., Kiley, J. P., Mockrin, S. C., Lauer, M. S., Mensah, G. A., Patel, Y., Cook, N. L., Patterson, A. P., & Gibbons, G. H. (2015) · Blood · doi:10.1182/blood-2015-02-626689 · Cited by 3
Atherosclerosis: Is a cure in sight?
Wilson, D. P., & Gidding, S. S. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.06.010 · Cited by 3
Han, Y., Qi, R., & Liu, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.147 · Cited by 3
Next-generation gene discovery for variants of large impact on lipid traits
Rosenthal, E. A., Blue, E., & Jarvik, G. P. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000156 · Cited by 3
From exomes to genomes: challenges and solutions in population-based genetic association studies
Auer, P. L., & Leal, S. M. (2017) · European Journal of Human Genetics · doi:10.1038/ejhg.2016.206 · Cited by 3
Human genes lost and their functions found
Plenge, R. M. (2017) · Nature · doi:10.1038/544171a · Cited by 3
Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia
Yang, S., & Moon, Y.-A. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0353-5 · Cited by 3
The forkhead box O family in insulin action and lipid metabolism
Lee, S., Zhu, C., Yamauchi, J., Zhu, P., Feng, X., Qu, S., & Dong, H. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00013-0 · Cited by 3
Shou, W., Zhang, C., Shi, J., Wu, H., & Huang, W. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.11.010 · Cited by 3
Rahman, M. O., Ahmed, S., Mazumder, T., Salam, M. A., Baral, P. K., Rana, M. F., Mitra, S., Hossain, S., Rahman, R., & Hussain, M. S. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100191 · Cited by 3
Hypertriglyceridemia – a new and important present
Васильевна, Ц. О., Apartseva, N. E., & As, A. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-4-99-111 · Cited by 4
Effects of evolving lipid-lowering drugs on carbohydrate metabolism
Tsimihodimos, V., & Elisaf, M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.012 · Cited by 2
Alternative Natural Management of Dyslipidemia
Al-Kushi, A. G. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82430 · Cited by 4
Wang, X., Ren, S., Yang, X., Masoudi, A., Xue, X., Li, M., Li, H., Zhang, X., Wang, H., & Liu, J. (2021) · The Protein Journal · doi:10.1007/s10930-020-09952-7 · Cited by 3
A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 3
Recruiting a transcription factor in the liver to prevent atherosclerosis
Attie, A. D. (2021) · Journal of Clinical Investigation · doi:10.1172/jci154677 · Cited by 3
Pharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
hiPSC-Based Tissue Organoid Regeneration
Qu, Y., Yucer, N., Garcia, V. J., Giuliano, A. E., & Cui, X. (2018) · InTech eBooks · doi:10.5772/intechopen.76997 · Cited by 3
Toroghi, M. K., Bosley, J., Powell, L. M., Zhang, Y., Yang, F., Pu, X., Davis, J. D., & Al-Huniti, N. H. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12694 · Cited by 2
Residual Cardiovascular Risk Factors in Dyslipidemia
Nguyen, V. S., Tran, X. T., Vo, T. D., & Le, Q. T. C. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100046 · Cited by 3
RETRACTED ARTICLE: Relationship between the development of hyperlipidemia in hypothyroidism patients
Su, X., Chen, X., & Wang, B. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07423-z · Cited by 3
RetractedTocilizumab‐related hypertriglyceridemia is independent of key molecules regulating lipid metabolism
Ferraz‐Amaro, I., Santos‐Concepción, S., Castro‐Hernández, J., Hernández-Hernández, V., Segura, B. T., Luna, C., Delgado-Frías, E., & Díaz‐González, F. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14006 · Cited by 2
Nordestgaard, B. G., & Varbo, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_8 · Cited by 3
Darabi, M., Zakiev, E., & Kontush, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_18 · Cited by 3
Rader, D. J., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00001-9 · Cited by 3
Polygenic Hyperlipidemias and Coronary Artery Disease RiskPreprint
Ripatti, P., Rämö, J. T., Mars, N., Söderlund, S., Benner, C., Surakka, I. L., Kiiskinen, T., Havulinna, A. S., Palta, P., Freimer, N. B., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/735167 · Cited by 3
Loss-of-function of MFGE8 and protection against coronary atherosclerosisPreprint
Ruotsalainen, S., Surakka, I. L., Mars, N., Karjalainen, J. M., Kurki, M., Kanai, M., Krebs, K., Mishra, P. P., Mishra, B. H., Sinisalo, J. P., et al. (2021) · medRxiv · doi:10.1101/2021.06.23.21259381 · Cited by 3
Das, A., Gupta, M. D., Shaha, M., Lima, A., Miazi, O. F., & Das, G. B. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.09.523278 · Cited by 3
Hipertrigliceridemia (> 150 mg/dl) como marcador de riesgo cardiovascular
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500822 · Cited by 2
Leiviskä, J., Sundvall, J., Jauhiainen, M., Kotseva, K., Tuomilehto, J., Backer, G. D., Tokgözoğlu, L. S., Reiner, Ž., & Bacquer, D. D. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120653 · Cited by 2
D’Erasmo, L., Tramontano, D., & Arca, M. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000941 · Cited by 2
Liu, Y., Skudder‐Hill, L., Ko, J., Shamaitijiang, X., Sequeira, I. R., & Petrov, M. S. (2025) · Nutrients · doi:10.3390/nu17233718 · Cited by 2
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Alterman, J. F., Gross, K. Y., & Khvorova, A. (2026) · Nucleic Acid Therapeutics · doi:10.1177/21593337261435980 · Cited by 2
Emara, A., Mansour, A., Aboeldahab, H. A., Awashra, A., Abbas, O. F., Abdul‐Hafez, H. A., Alsubaiei, A. A., AlSejari, N., Saif, H. S., Shubietah, A. R. M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70716 · Cited by 2
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD
Saum, K. L., Pennathur, S., & Kanter, J. E. (2026) · Circulation Research · doi:10.1161/circresaha.126.327361 · Cited by 3
FNIP1 variants are associated with favourable metabolism in 1 million humans
Hindy, G., Adam, R. C., Sosina, O. A., Pryce, D. S., Blair, D., Herman, J., Lee, J., Dornbos, P., Mayerhofer, E., Gilly, A., et al. (2026) · Nature · doi:10.1038/s41586-026-10864-2 · Cited by 3
Twenty-five years of statins: where do we go from here?
Gotto, A. M., & Moon, J. E. (2015) · Clinical Lipidology · doi:10.2217/clp.14.62 · Cited by 2
HDL, heart disease, and the lung
Frey, K., & von Eckardstein, A. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100217 · Cited by 2
Asl, S. K., Rahimzadegan, M., & Asl, A. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28983 · Cited by 2
Shah, M. A., Sharma, A., Ayyad, M., Swartz, E., Jafrani, D., & Gala, D. (2024) · Cureus · doi:10.7759/cureus.67091 · Cited by 2
Costabile, G., Salamone, D., Pepa, G. D., Testa, R., Vitale, M., Brancato, V., Salvatore, M., Soricelli, A., Annuzzi, G., Rivellese, A. A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06464-w · Cited by 2
APOC3 inhibition: The strongest case yet for triglyceride targeting
Shapiro, M. D., & Slipczuk, L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.09.006 · Cited by 2
Bajaj, A., Oral, E. A., Brown, A. S., Gaudet, D., Alexander, V. J., Karwatowska‐Prokopczuk, E., & Baum, S. J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101352 · Cited by 2
Lipoproteins and Cardiovascular Disease Risk
Dhingra, R., & Vasan, R. S. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_4 · Cited by 2
Nedelkov, D., & Hu, Y.-M. (2019) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm-2019-0977 · Cited by 3
Kaltoft, M., Langsted, A., & Nordestgaard, B. G. (2022) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2022.2.e20 · Cited by 2
Genetic Influences on Blood Lipids and Cardiovascular Disease Risk
Pollin, T. I., Ordovás, J. M., & Guevara‐Cruz, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00026-6 · Cited by 2
ASGR1 - a new target for lowering non-HDL cholesterol
Hassan, M. S., & Wagdy, K. (2016) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.14 · Cited by 2
OBSOLETE: Bioinformatics Principles for Deciphering Cardiovascular Diseases
Yang, X. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99576-x · Cited by 2
Strategies for the use of nonstatin therapies
Pirillo, A., Norata, G. D., & Catapano, A. L. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000459 · Cited by 2
Genomics to Predict Risk of Coronary Artery Disease
Kessler, T., von Ameln, S., & Schunkert, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00002-0 · Cited by 2
A Novel Biomarker Approach to Exploit HDL for Risk Assessment
von Eckardstein, A. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.040 · Cited by 2
Human apolipoprotein CIII levels; evaluation of three assay methods
Sandin, Å., Olofsson, C., Strålfors, A., Ekberg, N. R., Brismar, K., Juntti‐Berggren, L., & Eggertsen, G. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1725976 · Cited by 2
Metadata
- Authors
- The TG and HDL Working Group of the Exome Sequencing Project, N. H.
- Corresponding author
- The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-03
- Volume
- 371
- Issue
- 1
- Pages
- 22-31
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4180269
- OpenAlex
- W2170009139
- Semantic Scholar
- b3c2b9d4976782980ff38a64e223209866004dcc
- Cited by
- 1,071
- References
- 66
- Citations by year
- 2026: 52 · 2025: 73 · 2024: 48 · 2023: 56 · 2022: 75 · 2021: 93 · 2020: 110 · 2019: 90 · 2018: 81 · 2017: 113 · 2016: 132 · 2015: 107 · 2014: 41
- FWCI
- 89.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- U.S. Department of Agriculture
- Massachusetts General Hospital (R01HL107816)
- University of Wisconsin-Milwaukee
- George Washington University
- University of Washington
- Donovan Family Foundation
- University of Ottawa
- Norges Teknisk-Naturvitenskapelige Universitet
- Queen Mary University of London
- Wellcome Trust
- Deutsches Zentrum für Herz-Kreislaufforschung
- Università degli Studi di Milano
- University of Texas Health Science Center at Houston
- Broad Institute
- Russell and Diana Hawkins Family Foundation
- National Institute for Health and Care Research (NF-SI-0611-10170)
- British Heart Foundation
- University of Leicester
- University of Oxford
- University of Leeds
- Fondation Leducq (T32HL007208)
- Lunds Universitet
- Hjärt-Lungfonden
- King Abdulaziz University
- Universität zu Lübeck
- Umeå Universitet
- Technische Universität München
- Università degli Studi di Verona
- Rheinische Friedrich-Wilhelms-Universität Bonn
- Novo Nordisk Fonden (NNF14OC0009819, NNF13OC0005339, NNF14OC0011049)
- Regione Emilia-Romagna
- National Institutes of Health (1rc2hl103010-01)
- School of Medicine, Stanford University
- University of North Carolina at Chapel Hill
- Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai
- Canadian Institutes of Health Research
- Medical Research Council
- Barts and The London School of Medicine and Dentistry
- Helmholtz Zentrum München
- National Institute on Aging (P30AG010129, U01AG049505)
- National Heart, Lung, and Blood Institute (HL 102923, RC2HL102925, HL-102924, K08HL114642, RC2HL102926, RC2HL102923, RC2HL-103010, HL 103010, RC2HL102924, R01HL107816, T32HL007208, R01HL109946)
- National Cancer Institute (R01CA082659)
- National Institute of Neurological Disorders and Stroke (R01NS017950)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein C-III, loss-of-function mutations, plasma triglycerides, coronary artery disease, rare variants, splice site mutation, nonsense mutation, missense mutations, genetic risk, European ancestry, African ancestry
- MeSH terms
- Coronary Disease, Genotype, Heterozygote, Humans, Liver, Mutation, Risk Factors, Triglycerides, Sequence Analysis, DNA, Black People, White People, Apolipoprotein C-III, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
